An observational study in Triple Negative Breast Cancer, sponsored by Vall d'Hebron Institute of Oncology. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.
Sponsored by Vall d'Hebron Institute of Oncology · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Triple Negative Breast Neoplasms with a site in Spain — 24 open to participants now, 48 under way, 10 of them phase 3. Triple Negative Breast Neoplasms · Spain.
Among the 136 studies in Triple Negative Breast Neoplasms with a site in Spain, this one is one of 7 that started in 2023, is one of 2 observational ones, reaches primary completion later than 7 of the 47 other live ones, and was the 112th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →24 of the 136 studies in Triple Negative Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
IDEAYA Biosciences · Sites in Spain, United States, Georgia
Ages 18+
Pfizer · Sites in Spain, United States, France
Ages 18+
Bristol-Myers Squibb · Sites in Spain, United States, Argentina and 25 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 38 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 59 · Phase 3 24
First in 2010; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 150 across the 134 interventional studies, 350 across the 2 observational. Of the 88 that completed or were terminated, 45 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 136 have an industry lead sponsor. The 10 most frequent:
Vall d'Hebron Institute of Oncology is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Vall d'Hebron Institute of Oncology has 1 study filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Triple Negative Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT04595565Phase 3GBG Forschungs GmbHSacituzumab Govitecan in Primary HER2-negative Breast Cancer | 2027-03-30 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT05916755Vall d'Hebron Institute of OncologyPredictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
Add all 20 to your calendar (.ics) → With an account.
Among the 136 studies in Triple Negative Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.
The combination of pembrolizumab, an immune checkpoint inhibitor (ICI), with neoadjuvant chemotherapy (NACT) increases pathologic complete response (pCR) and event-free survival (EFS) in patients with early triple negative breast cancer (eTNBC). However, not all patients equally benefit from a treatment that may have relevant adverse events (AEs).
Objectives: (1) To establish predictive biomarkers of response to NACT + ICI in eTNBC by correlating data coming from different layers of omics performed in different tissues, together with imaging, with pCR, EFS, and overall survival (OS). (2) To integrate data generated from (1), and clinical data, and explore multivariate predictive models of response to NACT + ICI.
Methods: Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included. Collected samples and type of analysis: (1) Tumor tissue (baseline and from residual disease after NACT): whole genome sequencing (WGS) and RNA-Seq will be performed (Hartwig sequencing platform and analytical pipeline), tissue immune phenotyping (PD-L1, T and B infiltrating lymphocytes, among others), and microbiome analysis (16S rRNA); (2) Blood (before and during NACT): circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), T-cell receptor beta (TCR-β) repertoire sequencing and analysis (ImmunoSeq hsTCRβ kit and immunoSEQ), and peripheral blood mononuclear cells (PBMCs) phenotyping; (3) Stools and saliva (before and during NACT): microbiome analysis (16S rRNA); (4) Breast MRI imaging (before and after NACT): radiomics analysis. Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs. The aim is to provide more personalized treatment efficacy and risk for relapse estimates.
Expected outcome: To develop a clinical tool to assist clinicians in the process of treatment decision-making in eTNBC, in order to maximize patient's benefit and quality of life, while minimizing AEs and financial burden to the health system.
Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pembrolizumab + neoadjuvant chemotherapy
Diagnostic Test: Whole Genome Sequencing · Diagnostic Test: RNA-Sequencing · Diagnostic Test: Microbiome analysis · Diagnostic Test: ctDNA analysis · Diagnostic Test: TCR-β repertoire sequencing · Diagnostic Test: PBMCs phenotyping · Drug: Pembrolizumab · Drug: Chemotherapy
Neoadjuvant chemotherapy
Diagnostic Test: Whole Genome Sequencing · Diagnostic Test: RNA-Sequencing · Diagnostic Test: Microbiome analysis · Diagnostic Test: ctDNA analysis · Diagnostic Test: TCR-β repertoire sequencing · Diagnostic Test: PBMCs phenotyping · Drug: Chemotherapy
Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
Also known as: WGS
RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
ctDNA analysis will be performed in plasma before and during NACT.
TCR-β repertoire sequencing will be performed in plasma before and during NACT.
PBMCs phenotyping will be performed in plasma before and during NACT.
Pembrolizumab will be given in combination with standard NACT.
Standard NACT will be given.
Also known as: Carboplatin, taxane, anthracycline, cyclophosphamide
Pathologic complete response (pCR) rate at definitive surgery
The rate (given as a percentage) of patients with a pCR at definitive surgery using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) from the American Joint Committee on Cancer (AJCC) staging criteria
Time frame: after neoadjuvant treatment and surgery, up to approximately 27-30 weeks
Event-free survival (EFS)
EFS is defined as the time from the start of neoadjuvant treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause
Time frame: Up to approximately 60 months
Overall survival (OS)
OS is defined as the time from starting neoadjuvant treatment until death due to any cause
Time frame: Up to approximately 60 months
Identification of biomarkers to predict clinical outcomes (pCR at definitive surgery, EFS, OS).
The clinical data (pCR at definitive surgery, EFS, OS) will be integrated with the results from the multiomics platform and multivariate predictive models of response to neoadjuvant chemotherapy (NACT) + immune checkpoint inhibitor (ICI) will be explored. Precisely, the multiomics platform will analyze: 1. RNA-Sequencing of the initial tumor and residual disease (if present) 2. microbiome analysis of the saliva and feces, 3. circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), 4. Tissue immune phenotyping, 5. T-cell receptor beta (TCR-β) repertoire sequencing and analysis using ImmunoSeq hsTCRβ kit and immunoSEQ, 6. Breast MRI imaging (before and after NACT), Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs.
Time frame: After all data are analyzed, up to approximately 60 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →
Vall d'Hebron Institute of Oncology